Biological therapy of inflammatory bowel disease

Polskie Archiwum Medycyny Wewnetrznej

Volumn 119, Issue 1-2, 2009, Pages 84-89

  Owczarek, Danuta ^a,b   Cibor, Dorota ^a   Szczepanek, Małgorzata ^a   Mach, Tomasz ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Biological therapy; Crohn's disease; Ulcerative colitis

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; ALICAFORSEN; ATLIZUMAB; AZATHIOPRINE; BASILIXIMAB; CERTOLIZUMAB PEGOL; DACLIZUMAB; ENTECAVIR; ETANERCEPT; FONTOLIZUMAB; GLUCOCORTICOID; GOLIMUMAB; INFLIXIMAB; LAMIVUDINE; MACROGOL; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; MLN 02; NATALIZUMAB; ONERCEPT; PLACEBO; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VISILIZUMAB;

BACTERIAL INFECTION; BIOLOGICAL THERAPY; BLOOD TRANSFUSION REACTION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CROHN DISEASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; HEPATITIS B; HUMAN; LUPUS LIKE SYNDROME; LYMPHOMA; MYCOSIS; NEOPLASM; PATHOGENESIS; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; TUBERCULOSIS; ULCERATIVE COLITIS;

EID: 61349111301     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.614     Document Type: Review

References (33)

1. Abreu MT, Sparrow MP. Translational research in inflammatory bowel disease. Mt Sinai J Med. 2006; 78: 1067-1072.
2. Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev. 2002; 15: 79-94.
3. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002; 347: 417-429.
4. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 1998; 115: 182-205.
5. Shanahan F. Inflammatory bowel disease; immunodiagnostics, immunotherapeutic and ecotherapeutics. Gastroenterology. 2001; 120: 622-636.
6. Yen D, Cheung J, Scheerens H, et al. lnterleukin-23 is essential for T cell-mediated colitis and promotes inflammation via interleukin-17 and interleukin 6. J Clin Invest. 2006; 116: 1310-1316.
7. Kurtovic J, Segal I. Recent advances in biological therapy for inflammatory bowel disease. Trop Gastroenterol. 2004; 25: 9-14.
8. Sandbory WJ, Targan SR. Biologic therapy in inflammatory bowel disease. Gastroenterology. 2002; 122: 1592-1608.
9. Desilva S, Kaplan G, Panaccione R. Sequential therapies for Crohn's disease: optimizing conventional and biologic strategies. Rev Gastroenterol Disord. 2008; 8: 109-116.
10. Arniuzzi A, De Pascalis B, Fedeli P, et al. Infliximab in Crohn's disease: early and long-term treatment. Dig Liver Dis. 2008; 40: 271-279.
11. Shergill AK, Terdiman JP. Controversies in the treatment of Crohn's disease: the case for an accelerated step-up treatment approach. World J Gastroenterol. 2008; 14: 2670-2677.
12. Caviglia R, Boskoski I, Cicala M. Long-term treatment with infliximab in inflammatory bowel disease: safety and tolerability issues. Expert Opin Drug Saf. 2008;7: 617-632.
13. Bartnik W. [Guidelines for inflammatory bowel disease management]. Gastroenterol Pol. 2007; 14: 3-13. Polish.
14. Van Deventer SJH. Tumor necrosis factor and Crohn's disease. Gut. 1997; 40:443-448.
15. Armstrond AM, Gardiner KR, Kirk SJ, et al. Tumor necrosis factor and inflammatory bowel disease. Br J Surg. 1997; 84: 1051 -1058.
16. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999; 340: 1398-1405.
17. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet. 2002; 359:1541-1549.
18. Hanauer SB, Sandborm WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumabl in Crohn's disease: the CLASSIC-1 trial. Gastroenterology. 2006; 130: 323-333.
19. Colombel JF, Sandborm WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007; 132: 52-65.
20. D'Haens GD, Swijsen C, Norman M, et al. Etanercept in the treatment of active refractor/ Crohn's disease: Asingle center pilot trial. Am J Gastroenterol. 2001; 96: 2564-2568.
21. Sandbom WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001; 121: 1088-1094.
22. Rutgeerts P, Sandbom WJ, Fedorak RN, et al. Onercept for moderate - to severe Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2006; 4: 888-893.
23. Rutgeerts P, Lemmens L, Van Assche G, et al. Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumor necrosis factor receptor): results of a randomized, open-label, pilot study. Aliment Pharmacol Ther. 2003; 17: 185-192.
24. Osterman MT, Lichtenstein GR. Current and future anti-TNF therapy for inflammatory bowel disease. Curr Treat Options Gastroenterol. 2007; 10: 195-207.
25. Stak WA, Mann SD, Roy AJ, et al. Randomised controlled trial of CDP571 antibody to tumor necrosis factor-alpha in Crohn's disease. Lancet. 1997; 349: 521-524.
26. Sandbom WJ, Feagan BG, Radford-Smith G, et al. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut. 2004; 53: 1485-1493.
27. Feagan BG, Sandbom WJ, Lichtenstein G, et al. CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther. 2006; 1: 617-628.
28. Schreiber S, Rutgeerts P, Fedorak R, et al. A randomized, placebo - controlled trial of certolizumab pegol (COP870) for treatment of Crohn's disease. Gastroenterology. 2005; 129: 807-814.
29. Rutgeerts R Schreiber S, Feagan B, et al. Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNF alpha, improves health-related quality of life in patients with moderate to severe Crohn's disease. Int J Colorectal Dis. 2008; 23: 289-296.
30. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007; 19: 296-298.
31. Blick SK, Curran MR Certolizumab pegol: in Crohn's disease. Bio Drugs. 2007;21: 195-201.
32. Abreu MT. Crohn's disease in patients who fail infliximab therapy: what does the future hold? Rev Gastroenterol Disord. 2007; 7: 20-26.
33. Kay J, Matteson EL, Dasgupta B, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2008; 58: 964-975.